

Birth weight influences cardiac structure, function, and disease risk: evidence of a causal association

Maddalena Ardissino ^{1,2†}, Alec P. Morley^{2†}, Eric A.W. Slob^{3,4,5,6},
Art Schuermans^{7,8,9}, Bilal Rayes¹, Zahra Raisi-Estabragh^{10,11},
Antonio de Marvao^{12,13,14}, Stephen Burgess ^{3,15}, Tormod Rogne ¹⁶,
Michael C. Honigberg^{7,8,17}, and Fu Siong Ng ^{1*}

¹National Heart and Lung Institute, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK; ²Department of Medicine, School of Clinical Medicine, University of Cambridge, UK; ³Medical Research Council Biostatistics Unit, University of Cambridge, UK; ⁴Department of Applied Economics, Erasmus School of Economics, Erasmus University Rotterdam, the Netherlands; ⁵Erasmus University Rotterdam Institute for Behavior and Biology, Erasmus University Rotterdam, the Netherlands; ⁶Erasmus School of Social and Behavioural Sciences, Erasmus University Rotterdam, the Netherlands; ⁷Department of Cardiovascular Sciences, KU Leuven, Flanders, Leuven, Belgium; ⁸Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA; ⁹Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; ¹⁰William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, UK; ¹¹Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, UK; ¹²Department of Women and Children's Health, King's College London, UK; ¹³British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, King's College London, UK; ¹⁴Medical Research Council, London Institute of Medical Sciences, Imperial College London, UK; ¹⁵Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK; ¹⁶Department of Chronic Disease Epidemiology, Yale School of Public Health, USA; and ¹⁷Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

Received 14 June 2023; revised 9 September 2023; accepted 10 September 2023; online publish-ahead-of-print 20 September 2023

See the editorial comment for this article 'On the importance of birth weight in relation to disease risk in later life', by M. Kavousi and H. Snieder, <https://doi.org/10.1093/eurheartj/ehad785>.

Abstract

Background and Aims Low birth weight is a common pregnancy complication, which has been associated with higher risk of cardiometabolic disease in later life. Prior Mendelian randomization (MR) studies exploring this question do not distinguish the mechanistic contributions of variants that directly influence birth weight through the foetal genome (direct foetal effects), vs. variants influencing birth weight indirectly by causing an adverse intrauterine environment (indirect maternal effects). In this study, MR was used to assess whether birth weight, independent of intrauterine influences, is associated with cardiovascular disease risk and measures of adverse cardiac structure and function.

Methods Uncorrelated ($r^2 < .001$), genome-wide significant ($P < 5 \times 10^{-8}$) single nucleotide polymorphisms were extracted from genome-wide association studies summary statistics for birth weight overall, and after isolating direct foetal effects only. Inverse-variance weighted MR was utilized for analyses on outcomes of atrial fibrillation, coronary artery disease, heart failure, ischaemic stroke, and 16 measures of cardiac structure and function. Multiple comparisons were accounted for by Benjamini–Hochberg correction.

Results Lower genetically-predicted birth weight, isolating direct foetal effects only, was associated with an increased risk of coronary artery disease (odds ratio 1.21, 95% confidence interval 1.06–1.37; $P = .031$), smaller chamber volumes, and lower stroke volume, but higher contractility.

Conclusions The results of this study support a causal role of low birth weight in cardiovascular disease, even after accounting for the influence of the intrauterine environment. This suggests that individuals with a low birth weight may benefit from early targeted cardiovascular disease prevention strategies, independent of whether this was linked to an adverse intrauterine environment during gestation.

* Corresponding author: Email: f.ng@imperial.ac.uk

† The first two authors contributed equally to the study.

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Structured Graphical Abstract

Key Question


Is birth weight, independent of intrauterine influences, associated with cardiovascular disease risk and measures of adverse cardiac structure and function?

Key Finding

Lower birth weight, even after accounting for the influence of the intrauterine environment, was associated with higher risk of coronary artery disease, lower risk of atrial fibrillation and adverse measures of cardiac function.

Take Home Message

At risk individuals with a low birth weight may benefit from early targeted cardiovascular disease prevention strategies, independent of whether this was linked to an adverse intrauterine environment during gestation.



Mendelian randomization study evaluating the causal relevance of birth weight on cardiovascular structure function and disease risk. UKB, UK Biobank; EGG, Early Growth Genetics Consortium; MRI, magnetic resonance imaging.

Keywords

Cardiac MRI • Birth weight • Mendelian randomization • Genetic effects • Maternal • Foetal • Intrauterine

Introduction

Low birth weight is a common pregnancy complication, affecting ~15% of live births globally.¹ Multiple observational studies have described that low birth weight is associated with higher risk of cardiometabolic disease in later life.^{2–5} These findings have given rise to the Developmental Origins of Health and Disease (DOHaD) hypothesis, suggesting that adverse intrauterine environment and nutritional deprivation during foetal growth promote a series of metabolic adaptations that ultimately foster the development of cardiovascular disease.⁶ The majority of data supporting this hypothesis is derived from observational studies.^{2–5} However, in the observational setting, it is difficult to definitively establish that this relationship is causal. It is well recognized that both birth weight and cardiovascular disease risk are strongly influenced by many notoriously difficult-to-measure

economic and socio-behavioural factors, almost certainly contributing to a degree of residual confounding.

Mendelian randomization (MR) is a genetic epidemiological method that leverages the random process of allele assortment at conception, which leads to an effective 'randomization' of individuals to high or low genetic risk of a phenotype such as low birth weight, to help establish causality.⁷ This effective randomization limits the liability to influence by reverse causation and confounding and can therefore provide evidence to support a causal association between the exposure and outcome in question.^{8,9} In previous MR studies, lower birth weight has been associated with higher risk of coronary artery disease,^{10–12} but conversely a lower risk of atrial fibrillation.¹³

Though these studies address the issue of observational confounding and suggest a causal role supporting the DOHaD hypothesis, they are limited by the lack of adjustment for the expected correlation between

maternal and foetal phenotypes. Indeed, in a genome-wide association study (GWAS) on individuals' birth weight, the genetic effects will include a mixture of (i) genetic variants that directly influence birth weight through the foetal genome, (ii) maternal genetic variants that promote an adverse intrauterine environment, which will be correlated with foetal genotype ($r = \sim .5$, due to direct inheritance during conception), and (iii) paternal effects, which have been shown to be negligible.¹⁴ All available MR studies to date have not differentiated these effects,^{10–13} except for one study exploring cardiovascular risk factors but not outcomes.¹⁵ For this reason, currently available data do not provide any mechanistic information about whether the association is driven by direct effects of birth weight, by an adverse intrauterine environment, or both.

Recently, two GWAS studies have specifically isolated the variants that exert genetic effects through the foetal genome from those related to adverse intrauterine environments. First, Warrington *et al.*¹⁴ utilized structural equation modelling to adjust for indirect maternal influences in the genetic effects on birth weight, thus isolating the direct foetal effects only in a GWAS in participants of the Early Growth Genetics (EGG) Consortium and the UK Biobank (UKB). More recently, Juliusdottir *et al.*¹⁶ used a clustering-based method to identify variants affecting birth weight through the foetal genome only, separating these from variants influencing birth weight through maternal or paternal genomes, in the Icelandic birth register cohort. To date, two investigations have adopted the former study in MR analyses. These were aimed at assessing associations with cardiometabolic risk factors, and both studies identified that lower birth weight, even after isolating direct foetal effects only, was associated with worse cardiometabolic profile.^{14,15} However, it is unclear whether this result might extend to overt cardiovascular disease and adverse cardiac remodelling.

In this study, we used large-scale genetic data to explore the association of lower birth weight, overall and after only isolating direct foetal effects, with cardiovascular diseases and with multiple cardiac magnetic resonance (CMR) imaging markers of structure and function. For the associations of low birth weight through direct foetal effects with cardiovascular outcomes, we aimed to explore (i) whether traditional cardiovascular risk markers mediate the association, and (ii) whether intervening on these factors in a clinical setting might mitigate the excess cardiovascular risk conferred by lower birth weight.

Methods

Study design

A summary of study data sources is provided in [Table 1](#). The paper is reported on the basis of recommendations by the Strengthening the Reporting of Observational Studies in Epidemiology using Mendelian Randomization (STROBE-MR) Guidelines.²⁸ All statistical analyses were performed using R v4.1.2²⁹ using the TwoSampleMR³⁰ and Mendelianrandomization packages.³¹ The *Structured Graphical Abstract* was created with BioRender.com.

Instrumental variable selection

For primary analysis, instrumental variants were extracted from Warrington *et al.*'s¹⁴ meta-analysis using the EGG Consortium and UKB. This study included 297 142 individuals with birth weight data, 257 753 of whom were used in a structural equation modelling approach to adjust the overall genetic association estimates for indirect maternal genetic influences, thus producing genetic association estimates that isolate only the

direct foetal genetic effects. The methods are described at the original publication.³² The measure of birth weight was z-transformed; and all models were adjusted for sex, gestational duration, and the first four ancestry-informative principal components (to capture population stratification). From the summary statistics of this study, genome-wide significant ($P < 5 \times 10^{-8}$) uncorrelated ($r^2 < .001$) variants were extracted as instrumental variables for the exposures of (i) birth weight overall measured in standard deviations, 155 single nucleotide polymorphisms (SNPs), and (ii) direct foetal genetic influence on birth weight, 25 SNPs. The analysis flowchart is depicted in [Figure 1](#).

A replication analysis was performed utilizing data from Juliusdottir *et al.*'s¹⁶ investigation which utilized a different methodology. In this study, a meta-analysis GWAS on own birth weight was performed including 423 683 individuals from the Iceland Birth Register, EGG Consortium, and UKB. For own birth weight, 199 uncorrelated ($r^2 < .001$) genome-wide significant ($P < 5 \times 10^{-8}$) instrumental variants were extracted from summary statistics of this analysis. Then, using phased genotype data of 104 920 parent-offspring trios, the authors analysed the maternal transmitted alleles, paternal transmitted alleles, and maternal non-transmitted alleles separately, formally testing which combination of alleles best explained the association with birth weight. Based on these results, the variants influencing birth weight were clustered using Gaussian mixture model-based clustering into eight separate clusters, based on the pattern of effect. Further description of the methods is available in the original publication. Among these, clusters 1, 2, and 3 included variants affecting birth weight through the foetal genome only. In the present study, the 80 uncorrelated ($r^2 < .001$) genome-wide significant ($P < 5 \times 10^{-8}$) instrumental variants in these three clusters were extracted for the analysis of direct foetal effects on birth weight. The flowchart for instrumental variable selection for the sensitivity analysis is depicted in [Supplementary data online, Figure S1](#).

Instrument strength was quantified using *F*-statistics. The *F*-statistic measures the ratio of the mean square of the model to the mean square of the error. The *F*-statistic for univariable analyses was calculated using the formula

$$F = \frac{(n - k - 1)}{k} \frac{(R^2)}{(1 - R^2)}$$

where R^2 is the explained variance in the regression of all SNPs, n is the number of participants in the study, k is the number of instrumental variants. The R^2 was calculated as the sum of SNP-wise R^2 of instruments, which is obtained as follows:

$$R^2 = \frac{F}{(n - 2 + F)} \text{ with } F = \left(\frac{\beta}{SE(\beta)} \right)^2.$$

where β represents the effect size of the genetic variant in the exposure GWAS, and $SE(\beta)$ represents the standard error of the effect size of the genetic variant in the exposure GWAS. For multivariable analyses, instrument strength was assessed using conditional *F*-statistics calculated using the multivariable Mendelian randomization (MVMR) package.^{33,34}

Study outcomes


Genetic association estimates for the cardiovascular outcomes were extracted from GWAS summary statistics for atrial fibrillation (60 620 cases and 970 216 controls),¹⁷ coronary artery disease (122 733 cases and 424 528 controls),¹⁸ heart failure (115 150 cases and 1 550 331 controls),¹⁹ and ischaemic stroke (34 217 cases and 406 111 controls).²⁰

Genetic association estimates for the majority of CMR parameters were extracted from publicly available GWAS summary statistics of Pirruccello *et al.*'s²¹ recent study in 45 504 participants in the UKB Imaging Cohort. The imaging outcomes considered included as follows: left ventricular end-

Table 1 Information on the studies and consortia from which genetic association data were obtained

Phenotype	Study or consortium	Ancestry	Cases/controls	Case definition	Control definition	Units	Link/PMID
Exposures							
Birth weight	Early Growth Genetics and UK Biobank ¹³	EUR	321 223	Own birth weight	n/a	1 SD	31043758
Birth weight: foetal effects only	Early Growth Genetics and UK Biobank ¹⁴	EUR	321 223	Own birth weight, after adjustment for maternal genetic effects using structural equation modelling	n/a	1 SD	31043758
Exposures for replication analysis							
Birth weight	Icelandic birth register, Early Growth Genetics, and UK Biobank ¹⁵	EUR	423 683	Own birth weight	n/a	1 SD	34282336
Birth weight: foetal effects only	Icelandic birth register, Early Growth Genetics, and UK Biobank ¹⁶	EUR	104 920	Own birth weight; selecting variants that only influence birth weight via foetal genome (clusters 1, 2, and 3)	n/a	1 SD	34282336
Outcomes							
Atrial fibrillation	Nielsen et al. ¹⁷	EUR	60 620/ 970 216	Clinically diagnosed atrial fibrillation or flutter UKB and HUNT cohorts: ICD-9 427.3 ICD-10 I48	No history of atrial fibrillation, flutter or other arrhythmias	Log(OR)	30061737
Coronary artery disease	Van der Harst et al. ¹⁸	EUR	122 733/ 424 528	Coronary artery disease or myocardial infarction	No known coronary artery disease or past myocardial infarction	Log(OR)	29212778
Heart failure	Levin et al. ¹⁹	EUR	115 150/ 550 331	Diagnosis of heart failure by physician, or healthcare record, and corroborated on self-report	No history of heart failure	Log(OR)	36376295
Ischaemic stroke	Malik et al. ²⁰	EUR	34 217/ 406 111	Any ischaemic stroke	No history of stroke, of any type	Log(OR)	29531354
Cardiac structure and function	Pirruccello et al. ²¹	EUR	45 504	UK Biobank participants	n/a	Log(OR)	35697867
Left atrial maximum volume and left atrial total ejection fraction	Ahlberg et al. ²²	EUR	35 658	UK Biobank participants	n/a	Log(OR)	34338756
Left ventricular mass	Khurshid et al. ²³	EUR	43 230	UK Biobank participants	n/a	Log(OR)	36944631
Mediators							
Body mass index	Pulit et al. ²⁴	EUR	434 794	n/a	n/a	1 SD	30239722
Height	Yengo et al. ²⁵	EUR	709 594	n/a	n/a	1 SD	30124842
Systolic blood pressure	Evangelou et al. ²⁶	EUR	757 601	n/a	n/a	1 mmHg	30224653
Type 2 diabetes	Mahajan et al. ²⁷	EUR	80 154/ 853 816	Type 2 diabetes	No history of type 2 diabetes	Log(OR)	35551307

EUR, European.



systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV), left ventricular stroke volume (LVSV), left ventricular ejection fraction (LVEF), right atrial maximum area (RA Max), right atrial minimum area (RA Min), right atrial fractional area change (RA FAC), right ventricular end-systolic volume (RVESV), right ventricular end-diastolic volume (RVEDV), right ventricular systolic volume (RVSV), right ventricular ejection fraction (RVEF), proximal pulmonary artery diameter, and ascending aorta diameter. Genetic association estimates for left atrial maximum volume (LA Max) and left atrial total ejection fraction (LATEF) were derived from Ahlberg *et al.*'s²² study on 35 658 individuals from the UKB Imaging Cohort. Genetic association estimates for left ventricular (LV) mass was derived from Khurshid *et al.*'s²³ study on 43 230 participants of the UKB Imaging Cohort. Cardiac magnetic resonance outcomes were selected based on the availability of large cohort GWAS summary statistics. All outcomes were indexed by body surface area; except LATEF, LVEF, RA FAC, and RVEF, which are dimensionless.

Mendelian randomization

Gene-exposure association data were individually harmonized with gene-outcome association using the TwoSampleMR package in R. During harmonization, the positive strand allele was inferred where this was possible, and where this was not possible, the SNP was not used in further analysis. Only SNPs with gene-exposure and gene-outcome association data present were used in the analysis.

Inverse-variance weighted (IVW) MR with multiplicative random effects was used as the primary analysis method to estimate the association between genetically-predicted birth weight (overall, and after isolating the direct foetal genetic effects) and each outcome.³⁵

For cardiovascular outcomes, results are presented as odds ratios (OR) with respective 95% confidence intervals (CIs). For the CMR measures, which are continuous, results are presented as coefficients (β) and 95% CI. All presented *P*-values are adjusted for multiple comparisons using

Benjamini–Hochberg correction for a false-discovery rate of 5% based on the number of tests performed for each exposure.

Sensitivity analyses

Sensitivity analyses were carried out using weighted median MR and MR-Egger. One of the core assumptions of the IVW MR approach is that genetic instruments are only associated with the outcome through the studied exposure. If genetic variants act through additional, 'parallel' biological pathways, these assumptions are violated due to horizontal pleiotropy. Sensitivity analysis using weighted median MR³⁶ and MR-Egger were performed to explore whether this was occurring. The weighted median method has been shown to provide consistent estimates when up to half of SNPs are invalid, or pleiotropic.³⁶ The MR-Egger method can be used to identify the presence of directional pleiotropy under a weaker assumption that the instrument strength is independent of direct effects (InSIDE assumption).³⁷ A significant *P*-value on MR-Egger intercept test suggests potential presence of directional pleiotropy.

Mediation analyses

Mediation analysis for any putative direct foetal genetic effects was performed using MVMR. These were performed only where a significant association was identified in the primary univariable analysis of direct foetal genetic effects. The potential mediators considered were chosen among the phenotypes that have been previously identified to associate with birth weight.¹⁴ These included body mass index (BMI)²⁴ ($n = 434\,794$, European ancestry), height²⁵ ($n = 709\,594$, European ancestry), systolic blood pressure (SBP)²⁶ ($n = 757\,601$, European ancestry), and type 2 diabetes mellitus (T2DM)²⁷ (80 154 cases and 853 816 controls, European ancestry). For each individual analysis, the mediators to include were based on biological plausibility of mediation based on a formally tested association between the exposure and mediator, and consistency of this with the direction of association on univariable analysis so as to represent a true potential mediating pathway.³⁸ For this analysis, we used EGG Consortium/UKB

meta-analysis data¹⁴ for direct foetal effects on birth weight, as these data provide genome-wide estimates adjusted for maternal indirect effects; this is in contrast to Juliusdottir *et al.*'s study¹⁶ where variants are selected if they have direct foetal effects, but the association estimates are not adjusted.

Multivariable MR was performed to estimate the effect of the exposure on the outcome after accounting for the mediator (reported as an adjusted OR with 95% CI). This was then qualitatively compared to the estimate of association in the main univariable inverse-variance weighted analysis. Substantial attenuation after conditioning by the mediator is taken to suggest the presence of a potential mediating pathway.³⁸

Results

Birth weight and cardiovascular outcomes

Lower genetically-predicted birth weight was associated with higher risk of coronary artery disease (OR 1.28 [1.17 to 1.41] $P = 6.75 \times 10^{-6}$), but lower risk of atrial fibrillation (OR 0.79 [0.72 to 0.87] $P = 1.25 \times 10^{-6}$). There were no statistically significant associations with heart failure (OR 1.04 [0.98 to 1.11] $P = .427$) or ischaemic stroke (OR 1.12 [0.99 to 1.26] $P = .292$). The results are reported in [Figure 2A](#).

After isolating direct foetal genetic effects, lower birth weight remained associated with higher risk of coronary artery disease (OR 1.21 [1.06 to 1.37] $P = 3.14 \times 10^{-2}$). The association with lower risk of atrial fibrillation (OR 0.84 [0.74 to 0.96] $P = .063$) remained consistent in direction and magnitude, however, was no longer statistically significant after accounting for multiple testing. There were no statistically significant associations with heart failure (OR 1.01 [0.93 to 1.10] $P = .890$) or ischaemic stroke (OR 0.95 [0.77 to 1.18] $P = .861$). The results are reported in [Figure 2B](#).

Birth weight and cardiac structure and function

For cardiac structure and function, all outcomes are presented as the change in the beta value per 1 SD lower birth weight. Lower genetically-predicted birth weight was associated with lower indexed left chamber volumes as follows: LVESV (β -0.15 [-0.22 to -0.08] $P = 3.23 \times 10^{-4}$), LVEDV (β -0.16 [-0.24 to -0.08] $P = 3.71 \times 10^{-4}$), and LVSV (β -0.12 [-0.19 to -0.04] $P = 8.53 \times 10^{-3}$). However, lower birth weight was associated with greater indexed LV mass (β $.09$ [0.02 to 0.17] $P = .022$).

Associations with right-sided measures followed a consistent pattern of lower indexed chamber volumes with lower birth weight as follows: RVESV (β -0.18 [-0.25 to -0.11] $P = 1.35 \times 10^{-5}$), RVEDV (β -0.17 [-0.25 to -0.10] $P = 1.05 \times 10^{-4}$), and RVSV (β -0.12 [-0.19 to -0.04] $P = 8.53 \times 10^{-3}$). Additionally, lower birth weight was associated with lower indexed RA areas, including indexed RA Max (β -0.13 [-0.21 to -0.06] $P = 2.82 \times 10^{-3}$) and indexed RA Min (β -0.15 [-0.22 to -0.07] $P = 3.23 \times 10^{-4}$). However, lower birth weight was associated with higher RA FAC (β $.08$ [0.02 to 0.14] $P = .018$) and RVEF (β $.09$ [0.03 to 0.15] $P = 9.22 \times 10^{-3}$).

Though there were statistically significant associations with other measures of cardiac function, the associations between birth weight and LA Max, LATEF, LVEF, proximal PA diameter, and ascending aorta diameter were not statistically significant. The results are reported in [Figure 3A](#).

When isolating the direct foetal genetic effects, only the association of lower birth weight with lower RA Max (β -0.17 [-0.28 to -0.07] $P = 4.71 \times 10^{-3}$), lower RA Min (β -0.24 [-0.33 to -0.14] $P = 1.35 \times 10^{-5}$), and higher RA FAC (β $.21$ [0.11 to 0.30]

$P = 1.05 \times 10^{-4}$) remained consistent with statistical significance despite the loss of power when accounting for multiple testing. The association with LV mass was reversed in direction (β -0.14 [-0.29 to 0.01] $P = .101$) although this failed to reach statistical significance and crossed the null. Associations with other variables remained consistent in direction and magnitude, but were no longer statistically significant, however, this is expected given the loss of power when accounting for multiple testing. The results are reported in [Figure 3B](#).

Replication and sensitivity analyses

The replication analysis using gene-exposure data from Juliusdottir *et al.*'s study produced consistent findings, except for the outcomes of ischaemic stroke and LV Mass as shown in [Supplementary data online, Figures S2 and S3](#). While the association between genetically-predicted birth weight and stroke was not significant on primary analysis, in the replication analysis, lower genetically-predicted birth weight was associated with a greater risk of stroke (OR 1.17 [1.05 to 1.31] $P = .018^2$). This association was not significant after isolating direct foetal effects only (OR 1.06 [0.90 to 1.24] $P = .580$), consistent with the primary analysis. The findings for LV mass were consistent with the direction of the primary analysis: lower genetically-predicted birth weight overall was associated with a higher LV Mass (β $.13$ [0.07 to 0.20] $P = 2.55 \times 10^{-4}$) but lower genetically-predicted birth weight through direct foetal effects was also associated with lower LV mass (β -0.13 [-0.23 to -0.03] $P = .021$). Notably, these results reached statistical significance in the replication analysis, despite only a suggestion of this reversal of effect in the main analysis where the direct foetal effects on LV mass followed a similar reversing pattern but failed to reach statistical significance.

The sensitivity analyses using weighted median MR and MR-Egger produced consistent estimates, and MR-Egger intercept test did not identify evidence suggestive of directional pleiotropy, as reported in [Supplementary data online, Table S1](#) for the main analyses, and [Supplementary data online, Table S2](#) for the replication analyses.

In the main analysis, the mean instrument F -statistic was 58 for birth weight overall, and 142 for birth weight after isolating direct foetal effects only. In the replication analysis, the instrument F -statistic for genetically-predicted birth weight was 91, and after isolating direct foetal effects only this was 100.

Mediation analysis

For the association of lower birth weight and higher risk of coronary artery disease, potential mediation was explored through SBP and T2DM, as these factors are known to be inversely associated with birth weight,¹⁴ but directly associated with coronary artery disease, and thus provide feasible pathways for mediation of an overall inverse association. On mediation analysis, the association between birth weight through direct foetal effects and coronary artery disease (unadjusted OR 1.21 [1.06 to 1.37] $P = .005$) was mildly attenuated after adjustment for T2DM (adjusted OR 1.19 [1.01 to 1.40] $P = .039$; conditional F -statistic for birth weight = 36.9), and to a greater degree after adjustment for SBP (adjusted OR 1.08 [0.91 to 1.28] $P = .400$; conditional F -statistic for birth weight = 46.1). This suggests that partial mediation might exist by both of the considered risk factors. The results are reported in [Figure 4A](#).

For the association between lower birth weight and lower risk of AF, potential mediation was explored through BMI and height, as these factors are both directly associated with birth weight,¹⁴ and are also




Figure 2 Mendelian randomization estimates for the effects of (A) genetically-predicted birth weight and (B) genetically-predicted birth weight after isolating only variants that act through direct foetal effects, on cardiovascular outcomes. SD, standard deviation

directly associated with higher risk of AF, and thus provide feasible pathways for mediation of an overall direct association. On mediation analysis, the association between birth weight through direct foetal effects and atrial fibrillation (unadjusted OR 0.84 [0.74 to 0.96] $P = .011$) was mildly attenuated after adjustment for BMI (adjusted OR 0.88 [0.77 to 1.02] $P = .088$; conditional F -statistic for birth weight = 53.5), and to a greater degree after adjusting for height (adjusted OR 0.92 [0.80 to 1.06] $P = .259$; conditional F -statistic for birth weight = 13.2). This suggests that partial mediation might exist by both of the considered risk factors. The results are reported in [Figure 4B](#).

Discussion

The purpose of this study was to further understand the mechanistic pathways underlying the association of birth weight with cardiovascular disease, with the specific aim of establishing whether birth weight had a direct, causal role on determining cardiovascular risk that is independent of the intrauterine environment. There are several key messages. First, the results suggest that birth weight has direct causal effects on cardiovascular disease that are independent of intrauterine exposures. This provides important insight regarding the mechanisms underlying




Figure 3 Mendelian randomization estimates for the effects of (A) genetically-predicted birth weight and (B) genetically-predicted birth weight after isolating only variants that act through direct foetal effects, on cardiovascular magnetic resonance imaging parameters of cardiac structure and function. LA Max, left atrial maximum volume; LATEF, left atrial total ejection fraction; LVESV, left ventricular end-systolic volume; LVEDV, left ventricular end-diastolic volume; LVSV, left ventricular stroke volume; LVEF, left ventricular ejection fraction; LV Mass, left ventricular mass; RA Max, right atrial maximum area; RA Min, right atrial minimum area; RA FAC, right atrial fractional area change; RVESV, right ventricular end-systolic volume; RVEDV, right ventricular end-diastolic volume; RVSV, right ventricular systolic volume; RVEF, right ventricular ejection fraction; Prox PA Diam, proximal pulmonary artery diameter; Asc Aorta Diam, ascending aorta diameter; SD, standard deviation

the DOHaD hypothesis. Though this result does not negate a potential role of the intrauterine environment, which might be a risk enhancer, or act to modify cardiovascular risk through independent pathways, they indicate that birth weight exerts at least some effects that are independent of the intrauterine environment. Second, we establish that the association of these direct foetal effects with coronary artery disease may be partly mediated by T2DM and SBP, identifying these as key targets for surveillance and targeted prevention. Third, we identify an association of higher birth weight with greater risk of atrial fibrillation, mediated by BMI and, to a greater extent, height. Finally, we provide evidence that low birth weight contributes to adverse cardiac remodelling, broadly following a pattern of smaller chamber volumes, lower stroke volumes, and greater contractility (*Structured Graphical Abstract*).

There are two major strengths. The first of these is its genetic epidemiological approach, which distinguishes it from the vast literature of prior observational studies exploring the cardiometabolic consequences of low birth weight. The use of MR in this setting mitigates the potential impact of confounding, which is an important concern when studying birth weight because there are many potential difficult-to-measure confounders that may influence the association between birth weight and cardiovascular disease. In the hierarchy of evidence, MR has been advocated as providing 'critical' evidence on risk factor–outcome relationships,⁷ especially when, as in this case, the risk factor in question is not practically or ethically amenable to randomization. The second strength is the specific investigation of the

direct effects of birth weight: this provides crucial mechanistic insight for the DOHaD hypothesis that has implications for risk stratification. Though it does not imply that intrauterine exposures have no influence, it does suggest that individuals with low birth weight are at enhanced risk whether their low birth weight is related to an adverse intrauterine environment or not. Finally, the investigations of potential modifiable mediating pathways add clinical relevance by identifying a number of key mediators that are amenable to intervention.

Lower genetically-predicted birth weight was associated with greater coronary artery disease risk. Conversely, higher genetically-predicted birth weight was associated with greater atrial fibrillation risk. These results are in line with observational evidence,^{2–6,39–44} as well as previous evidence from MR studies.^{10,13} Our study specifically adds by establishing a contribution of direct causal effects on birth weight. The association of lower birth weight with higher coronary artery disease risk is in line with a previous investigation of 26 057 mother–offspring pairs from the Nord-Trøndelag Health (HUNT) study, where Moen *et al.*¹⁵ demonstrated that offspring genetic risk score was independently associated with offspring cardiometabolic factors, including glycaemic and cholesterol traits, in models adjusting for maternal and paternal genetic risk scores. The pattern of these results mirrors ours, and we extend this work by revealing consistent findings for both disease outcomes and imaging markers of adverse cardiac structure and function.

Though the association of lower birth weight with lower risk of atrial fibrillation might not seem intuitively consistent with the result for




Figure 4 Mediation analysis utilizing multivariable Mendelian randomization, displaying estimates for the effects of genetically-predicted birth weight after isolating only direct foetal effects, on (A) coronary artery disease and (B) atrial fibrillation, before and after accounting for putative mediating factors. BMI, body mass index; T2DM, type 2 diabetes mellitus; SBP, systolic blood pressure; SD, standard deviation

coronary artery disease, it is directionally consistent with previous observational^{41,42} and MR studies.¹³ From a mechanistic perspective, it is also consistent with the known role of body anthropometric measures in determining risk of atrial fibrillation. It is indeed well recognized that greater body weight and height are strongly associated with atrial fibrillation risk.^{45–47} The important role of BMI and height in driving this association was highlighted in our mediation analysis, where we observed an attenuation in the magnitude of the association estimate after conditioning on BMI and, to a greater extent, height.

The association between low birth weight and cardiac structure and function has been studied in the observational setting. Recently, Raisi-Estabragh *et al.*⁴⁴ reported that in a cohort of 19 314 participants in the UKB, lower birth weight was associated with more concentric pattern of LV remodelling (higher LVM/LVEDV) and poorer LV function (lower LVSV index). Prior to this, the majority of available evidence remained restricted to preterm birth or small-for-gestational-age (SGA) individuals and preterm birth. In a study by Arnott *et al.*,⁴⁸

SGA adults had larger LV volumes and lower LVSV compared to individuals of average size for gestational age. Lewandowski *et al.* reported a greater LV mass, smaller chamber volumes, and worse LV strain in individuals with a history of preterm birth compared with controls,⁴⁹ findings that were replicated in relation to the atria,⁵⁰ in a subsequent study in an adolescent⁵¹ and a further adult cohort.⁵² Importantly, these changes are not benign: they have been shown to relate to a reduced myocardial functional reserve and an increase in diffuse myocardial fibrosis.^{53,54} However, we did not identify a significant association with heart failure. This might suggest that the adverse remodelling changes are subclinical in nature, but might also relate to insufficient power to detect an association. In our study, we additionally noted that with lower birth weight, despite smaller chamber volumes and stroke volumes, there was an association with metrics of greater contractility. Interestingly, prior observational work has identified similar patterns for preterm-born adults,⁵⁵ where despite smaller RA volumes, RA reservoir and booster strain were higher in the preterm cohort, suggesting

a degree of functional compensation for the smaller RA volumes. Prior observational evidence suggests that preterm-born adults, when exposed to physiologic stress, may exhibit a response of exaggerated contraction, possibly indicating compensation for reductions in volumetric reserve.^{50,55}

In the replication analysis, we noted that lower genetically-predicted birth weight overall was associated with greater LV mass. When isolating direct foetal genetic effects, this association was fully reversed, with lower genetically-predicted birth weight associating with lower LV mass. This reversal was present in the main analysis, with consistent magnitude and direction, though when isolating for direct foetal genetic effects, the association did not reach statistical significance. This reversal pattern is an intriguing finding, which we suggest that it might relate to differential vertically pleiotropic signals through SBP. The 'overall' genetically-predicted birth weight instruments include indirect maternal effects. Previous work conducted by Warrington *et al.*¹⁴ identified a strong generational effect relating to SBP and maternal genetic influences on birth weight: high maternal SBP was causally associated with lower offspring birth weight, and subsequent transmission of maternally-inherited SBP variants to the offspring begets higher offspring SBP in later life. Thus, when looking at birth weight overall, the maternally-inherited SBP genetic risk might feasibly drive the association with higher LV mass through the vertically pleiotropic phenotype of SBP. Subsequently, when isolating direct foetal genetic effects, we remove the influence of maternally-inherited SBP-associated alleles, and therefore, this influence is lost. Now, we expect predominantly anthropometric traits to drive the association. Thus, we observe a direct association, with lower genetically-predicted birth weight associated with lower LV mass (and conversely, high genetically-predicted birth weight associates with higher LV mass). Unfortunately, due to the lack of availability of individual-level data to isolate maternal genetic effects in the present study, this hypothesis could not be formally tested within the scope of our work. We therefore highlight this as a key research priority for individual-level studies.

There are some limitations to consider. First, in order to limit potential influence from population stratification, the data sources for our analysis were restricted to populations of European ancestry. Though this limits potential bias from population stratification, it means that the results may not be generalizable to populations of other ancestries. Second, the confidence with which causal relationships can be drawn from MR results depends on the plausibility of the instrumental variable assumptions.⁵⁶ We explored the first of these assumptions through checking instrument strength using *F*-statistics,³⁴ and the third of these through the use of multiple sensitivity analyses more robust to pleiotropy. In these analyses, we did not identify issues relating to weak instruments of directional pleiotropy and we therefore do not expect violation of this assumption. Third, the lack of individual-level data for the analyses is a limitation as it precludes formal quantification of the role of maternal effects on birth weight (and thus the intrauterine environment) as well as modelling of interactions between maternal and foetal genomes, or potentially non-linear effects. Fourth, because of the nature of the cardiovascular outcomes in the original GWASs, we could not formally quantify proportions mediated in the mediation analyses, due to the issue of non-collapsibility of OR in the setting of binary, non-rare outcomes. Fifth, when performing mediation analyses, it is important to note that attenuation of effects observed after adjustment for the potential mediator might not stem from true mediation (vertical pleiotropy) but rather from horizontal pleiotropy. The lack of evidence of horizontal pleiotropy in our sensitivity analyses supports a mediating, rather than horizontally pleiotropic, role of SBP and the other

phenotypes explored in the mediation analyses. Sixth, it is important to note that the magnitude of ORs represents lifetime associations that are not specific to particular age brackets or a defined time span. Thus, future studies are needed to investigate how the timing of cardiovascular risk might differ in individuals with low birth weight. Finally, due to the original design of the data sources used, there can be some 'healthy participant' bias, with the study volunteers being a higher socioeconomic status and healthier compared to the general population. This could lead to some bias in the effect size estimates.

From a clinical perspective, our study suggests that individuals born with low birth weight are at enhanced cardiovascular risk, independent of whether their low birth weight relates to intrauterine pathology. This encourages further consideration of birth weight in risk stratification for cardiovascular disease. It has been previously suggested that preterm-born individuals should be under more intensive follow up for early blood pressure control and routine surveillance of cardiovascular structure and function using echocardiography and cardiopulmonary exercise testing.⁵⁷ However, no guidelines currently use birth weight itself as a risk-enhancing factor; but observational—and now genetic—evidence suggests that this at-risk population might benefit from early targeted risk stratification and more aggressive prevention strategies. Within our study, we demonstrate that at least a part of the associations are mediated by modifiable risk factors including SBP and T2DM. This encourages early intervention on these factors in low birth weight individuals, as this is likely to at least partly mitigate the enhanced cardiovascular risk related to low birth weight.

In our study, we utilized MR to investigate the relationship between birth weight and cardiovascular disease, and we describe several direct, causal associations between birth weight and cardiovascular disease that are independent of the intrauterine environment. We also investigate the relationship between birth weight and 16 measurements of cardiac structure and function. Our findings suggest that lower birth weight plays a direct, causal role in the development of coronary artery disease, but that conversely higher birth weight is associated with atrial fibrillation. These direct associations provide insight into them mechanisms underlying the DOHaD hypothesis, suggesting that low birth weight is causally related to cardiovascular disease risk and cardiac structure and function, even after isolating out the potential effects of the intrauterine environment. Importantly, we also identify a number of modifiable cardiometabolic mediators that provide important targets for early intervention in the clinical setting.

Acknowledgements

We thank all investigators and participants of the Icelandic birth register, UK Biobank, CARDIOGRAM/C4D, MEGASTROKE, AFGen, and HERMES, and Early Growth Genetics consortia. The MEGASTROKE project received funding from sources specified at <https://www.megastroke.org/acknowledgements.html>. The views expressed are those of the authors and not necessarily those of King's Health Partners, Guy's and St Thomas's Hospital, the NHS, the National Institute for Health and Care Research (NIHR), or the Department of Health and Social Care.

Supplementary data

Supplementary data are available at *European Heart Journal* online.

Declarations

Disclosure of Interest

All authors declare no conflict of interest for this contribution.

Data Availability

Publicly available genome-wide association study (GWAS) summary data were utilized for the analyses.

These are available to download at cited sources.

Funding

M.A.: National Institute for Health Research Academic Clinical Fellowship and by the Fetal Medicine Foundation (495237). A.S., B.R., A.P.M., Z.R.E., T.R.: none to declare. A.d.M. is supported by the Fetal Medicine Foundation (495237) and Academy of Medical Sciences (SGL015/1006). M.C.H.: U.S. National Heart, Lung, and Blood Institute (K08HL166687), American Heart Association (940166, 979465). F.S.N.: British Heart Foundation (RG/F/22/110078, FS/CRTF/21/24183, and RE/19/4/34215) and the National Institute for Health Research Imperial Biomedical Research Centre.

Ethical Approval

Ethical approval and participant consent were obtained in the original studies that generated the data. Ethical approval for the use of summary-level data in our analysis was not required.

Pre-registered Clinical Trial Number

Not applicable.

References

- Blencowe H, Krasevec J, De Onis M, Black RE, An X, Stevens GA, et al. National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. *Lancet Global Health* 2019;**7**:e849–60. [https://doi.org/10.1016/s2214-109x\(18\)30565-5](https://doi.org/10.1016/s2214-109x(18)30565-5)
- Barker DJP, Godfrey KM, Gluckman PD, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in adult life. *Lancet* 1993;**341**:938–41. [https://doi.org/10.1016/0140-6736\(93\)91224-A](https://doi.org/10.1016/0140-6736(93)91224-A)
- Hales CN, Barker DJP. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. *Diabetologia* 1992;**35**:595–601. <https://doi.org/10.1007/BF00400248>
- Stuart A, Amer-Wählin I, Persson J, Källen K. Long-term cardiovascular risk in relation to birth weight and exposure to maternal diabetes mellitus. *Int J Cardiol* 2013;**168**:2653–7. <https://doi.org/10.1016/j.ijcard.2013.03.032>
- Risnes KR, Vatten LJ, Baker JL, Jameson K, Sovio U, Kajantie E, et al. Birthweight and mortality in adulthood: a systematic review and meta-analysis. *Int J Epidemiol* 2011;**40**:647–61. <https://doi.org/10.1093/ije/dyq267>
- Barker DJ. The fetal and infant origins of adult disease. *Br Med J* 1990;**301**:1111. <https://doi.org/10.1136/bmj.301.6761.1111>
- Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol* 2013;**37**:658–65. <https://doi.org/10.1002/gepi.21758>
- Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ* 2018;**362**:k601. <https://doi.org/10.1136/bmj.k601>
- Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al. Mendelian randomization. *Nat Rev Methods Primers* 2022;**2**:6. <https://doi.org/10.1038/s43586-021-00092-5>
- Zanetti D, Tikkanen E, Gustafsson S, Priest JR, Burgess S, Ingelsson E. Birthweight, type 2 diabetes mellitus, and cardiovascular disease: addressing the barker hypothesis with Mendelian randomization. *Circ Genom Precis Med* 2018;**11**:e002054. <https://doi.org/10.1161/circgen.117.002054>
- Pehkonen J, Viinikainen J, Kari JT, Böckerman P, Lehtimäki T, Viikari J, et al. Birth weight, adult weight, and cardiovascular biomarkers: evidence from the Cardiovascular Young Finns study. *Prev Med* 2022;**154**:106894. <https://doi.org/10.1016/j.ypmed.2021.106894>
- Zeng P, Zhou X. Causal association between birth weight and adult diseases: evidence from a Mendelian randomization analysis. *Front Genet* 2019;**10**:618. <https://doi.org/10.3389/fgene.2019.00618>
- Kember RL, Levin MG, Cousminer DL, Tsao N, Judy R, Schur GM, et al. Genetically determined birthweight associates with atrial fibrillation. *Circ Genom Precis Med* 2020;**13**:e002553. <https://doi.org/10.1161/CIRCGEN.119.002553>
- Warrington NM, Beaumont RN, Horikoshi M, Day FR, Helgeland Ø, Laurin C, et al. Maternal and fetal genetic effects on birth weight and their relevance to cardiometabolic risk factors. *Nat Genet* 2019;**51**:804–14. <https://doi.org/10.1038/s41588-019-0403-1>
- Moen GH, Brumpton B, Willer C, Åsvold BO, Birkeland KI, Wang G, et al. Mendelian randomization study of maternal influences on birthweight and future cardiometabolic risk in the HUNT cohort. *Nat Commun* 2020;**11**:5404. <https://doi.org/10.1038/s41467-020-19257-z>
- Juliusdottir T, Steinthorsdottir V, Stefansdottir L, Sveinbjornsson G, Ivarsdottir EV, Thorolfsdottir RB, et al. Distinction between the effects of parental and fetal genomes on fetal growth. *Nat Genet* 2021;**53**:1135–42. <https://doi.org/10.1038/s41588-021-00896-x>
- Nielsen JB, Thorolfsdottir RB, Fritsche LG, Zhou W, Skov MW, Graham SE, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. *Nat Genet* 2018;**50**:1234–9. <https://doi.org/10.1038/s41588-018-0171-3>
- van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circ Res* 2018;**122**:433–43. <https://doi.org/10.1161/circresaha.117.312086>
- Levin MG, Tsao NL, Singhal P, Liu C, Vy HMT, Paranjpe I, et al. Genome-wide association and multi-trait analyses characterize the common genetic architecture of heart failure. *Nat Commun* 2022;**13**:6914. <https://doi.org/10.1038/s41467-022-34216-6>
- Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multi-ancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* 2018;**50**:524–37. <https://doi.org/10.1038/s41588-018-0058-3>
- Pirruccello JP, Di Achille P, Nauffal V, Nekoui M, Friedman SF, Klarqvist MDR, et al. Genetic analysis of right heart structure and function in 40,000 people. *Nat Genet* 2022;**54**:792–803. <https://doi.org/10.1038/s41588-022-01090-3>
- Ahlberg G, Andreassen L, Ghouse J, Bertelsen L, Bundgaard H, Haunso S, et al. Genome-wide association study identifies 18 novel loci associated with left atrial volume and function. *Eur Heart J* 2021;**42**:4523–34. <https://doi.org/10.1093/eurheartj/ehab466>
- Khurshid S, Lazarte J, Pirruccello JP, Weng LC, Choi SH, Hall AW, et al. Clinical and genetic associations of deep learning-derived cardiac magnetic resonance-based left ventricular mass. *Nat Commun*. 2023; **14**:1558. <https://doi.org/10.1038/s41467-023-37173-w>
- Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet* 2019;**28**:166–74. <https://doi.org/10.1093/hmg/ddy327>
- Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700,000 individuals of European ancestry. *Hum Mol Genet* 2018;**27**:3641–9. <https://doi.org/10.1093/hmg/ddy271>
- Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nat Genet* 2018;**50**:1412–25. <https://doi.org/10.1038/s41588-018-0205-x>
- Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nat Genet* 2022;**54**:560–72. <https://doi.org/10.1038/s41588-022-01058-3>
- Davey Smith G, Davies NM, Dimou N, Egger M, Gallo V, Golub R, et al. STROBE-MR: guidelines for strengthening the reporting of Mendelian randomization studies. *PeerJ Preprints* 2019;**7**:e27857v27851. <https://doi.org/10.7287/peerj.preprints.27857v1>
- R Core Team. R: a language and environment for statistical computing. *Computing*. 2021; R Foundation.
- Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife* 2018;**7**:e34408. <https://doi.org/10.7554/eLife.34408>
- Yavorska OO, Burgess S. Mendelianrandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol* 2017;**46**:1734–9. <https://doi.org/10.1093/ije/dyx034>
- Warrington NM, Freathy RM, Neale MC, Evans DM. Using structural equation modelling to jointly estimate maternal and fetal effects on birthweight in the UK Biobank. *Int J Epidemiol* 2018;**47**:1229–41. <https://doi.org/10.1093/ije/dyy015>
- Sanderson E, Windmeijer F. A weak instrument F-test in linear IV models with multiple endogenous variables. *J Econom* 2016;**190**:212–21. <https://doi.org/10.1016/j.jeconom.2015.06.004>

34. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. *Stat Med* 2021;**40**:5434–52. <https://doi.org/10.1002/sim.9133>
35. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. *Stat Med* 2017;**36**:1783–802. <https://doi.org/10.1002/sim.7221>
36. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol* 2016;**40**:304–14. <https://doi.org/10.1002/gepi.21965>
37. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *Eur J Epidemiol* 2017;**32**:377–89. <https://doi.org/10.1007/s10654-017-0255-x>
38. Burgess S, Thompson DJ, Rees JMB, Day FR, Perry JR, Ong KK. Dissecting causal pathways using Mendelian randomization with summarized genetic data: application to age at menarche and risk of breast cancer. *Genetics* 2017;**207**:481–7. <https://doi.org/10.1534/genetics.117.300191>
39. Roseboom TJ, van der Meulen JH, Ravelli AC, Osmond C, Barker DJ, Bleker OP. Effects of prenatal exposure to the Dutch famine on adult disease in later life: an overview. *Mol Cell Endocrinol* 2001;**185**:93–8. [https://doi.org/10.1016/s0303-7207\(01\)00721-3](https://doi.org/10.1016/s0303-7207(01)00721-3)
40. Seghieri G, Anichini R, De Bellis A, Alviggi L, Franconi F, Breschi MC. Relationship between gestational diabetes mellitus and low maternal birth weight. *Diabetes Care* 2002;**25**:1761–5. <https://doi.org/10.2337/diacare.25.10.1761>
41. Lawani SO, Demerath EW, Lopez FL, Soliman EZ, Huxley RR, Rose KM, et al. Birth weight and the risk of atrial fibrillation in whites and African Americans: the Atherosclerosis Risk In Communities (ARIC) study. *BMC Cardiovasc Disord* 2014;**14**:69. <https://doi.org/10.1186/1471-2261-14-69>
42. Conen D, Tedrow UB, Cook NR, Buring JE, Albert CM. Birth weight is a significant risk factor for incident atrial fibrillation. *Circulation* 2010;**122**:764–70. <https://doi.org/10.1161/circulationaha.110.947978>
43. Li X, Yang R, Yang W, Xu H, Song R, Qi X, et al. Association of low birth weight with cardiometabolic diseases in Swedish twins: a population-based cohort study. *BMJ Open* 2021;**11**:e048030. <https://doi.org/10.1136/bmjopen-2020-048030>
44. Raisi-Estabragh Z, Cooper J, Bethell MS, McCracken C, Lewandowski AJ, Leeson P, et al. Lower birth weight is linked to poorer cardiovascular health in middle-aged population-based adults. *Heart* 2023;**109**:535–41. <https://doi.org/10.1136/heartjnl-2022-321733>
45. Larsson SC, Bäck M, Rees JMB, Mason AM, Burgess S. Body mass index and body composition in relation to 14 cardiovascular conditions in UK Biobank: a Mendelian randomization study. *Eur Heart J* 2019;**41**:221–6. <https://doi.org/10.1093/eurheartj/ehz388>
46. Marott JL, Skielboe AK, Diken U, Friberg JB, Schnohr P, Jensen GB. Increasing population height and risk of incident atrial fibrillation: the Copenhagen City Heart study. *Eur Heart J* 2018;**39**:4012–9. <https://doi.org/10.1093/eurheartj/ehy367>
47. Levin MG, Judy R, Gill D, Vujkovic M, Verma SS, Bradford Y, et al. Genetics of height and risk of atrial fibrillation: a Mendelian randomization study. *PLoS Med* 2020;**17**:e1003288. <https://doi.org/10.1371/journal.pmed.1003288>
48. Arnott C, Skilton MR, Ruohonen S, Juonala M, Viikari JS, Kähönen M, et al. Subtle increases in heart size persist into adulthood in growth restricted babies: the Cardiovascular Risk in Young Finns study. *Open Heart* 2015;**2**:e000265. <https://doi.org/10.1136/openhrt-2015-000265>
49. Lewandowski AJ, Augustine D, Lamata P, Davis EF, Lazdam M, Francis J, et al. Preterm heart in adult life. *Circulation* 2013;**127**:197–206. <https://doi.org/10.1161/CIRCULATIONAHA.112.126920>
50. Schuermans A, den Harink T, Raman B, Smillie RW, Alsharqi M, Mohamed A, et al. Differing impact of preterm birth on the right and left atria in adulthood. *J Am Heart Assoc* 2022;**11**:e027305. <https://doi.org/10.1161/JAHA.122.027305>
51. Goss KN, Haraldsdottir K, Beshish AG, Barton GP, Watson AM, Palta M, et al. Association between preterm birth and arrested cardiac growth in adolescents and young adults. *JAMA Cardiol* 2020;**5**:910–9. <https://doi.org/10.1001/jamacardio.2020.1511>
52. Mohamed A, Marciniak M, Williamson W, Huckstep OJ, Lapidaire W, McCance A, et al. Association of systolic blood pressure elevation with disproportionate left ventricular remodeling in very preterm-born young adults: the preterm heart and elevated blood pressure. *JAMA Cardiol* 2021;**6**:821–9. <https://doi.org/10.1001/jamacardio.2021.0961>
53. Huckstep OJ, Williamson W, Telles F, Burchert H, Bertagnolli M, Herdman C, et al. Physiological stress elicits impaired left ventricular function in preterm-born adults. *J Am Coll Cardiol* 2018;**71**:1347–56. <https://doi.org/10.1016/j.jacc.2018.01.046>
54. Lewandowski AJ, Raman B, Bertagnolli M, Mohamed A, Williamson W, Pelado JL, et al. Association of preterm birth with myocardial fibrosis and diastolic dysfunction in young adulthood. *J Am Coll Cardiol* 2021;**78**:683–92. <https://doi.org/10.1016/j.jacc.2021.05.053>
55. Barton GP, Corrado PA, Francois CJ, Chesler NC, Eldridge MW, Wieben O, et al. Exaggerated cardiac contractile response to hypoxia in adults born preterm. *J Clin Med* 2021;**10**:1166. <https://doi.org/10.3390/jcm10061166>
56. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;**44**:512–25. <https://doi.org/10.1093/ije/dyv080>
57. Lewandowski AJ, Levy PT, Bates ML, McNamara PJ, Nuyt AM, Goss KN. Impact of the vulnerable preterm heart and circulation on adult cardiovascular disease risk. *Hypertension* 2020;**76**:1028–37. <https://doi.org/10.1161/hypertensionaha.120.15574>

Erratum

<https://doi.org/10.1093/eurheartj/ehad443>

Online publish-ahead-of-print 11 July 2023

Erratum to: Smoking habit change after cancer diagnosis: effect on cardiovascular risk

This is an erratum to: Hyeok-Hee Lee and others, Smoking habit change after cancer diagnosis: effect on cardiovascular risk, *European Heart Journal*, Volume 45, Issue 2, 7 January 2024, Pages 132–135, <https://doi.org/10.1093/eurheartj/ehad199>

In the originally published version of this manuscript, the graphical abstract image had been removed but the references, “(Graphical Abstract)”, within the text to that image were not removed prior to publication.

These errors have been corrected in the article.

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com